Drugs & Targets Immunai to collaborate with Teva to enhance clinical decision making in immuno-oncology clinical trials November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves Aucatzyl for adults with r/r B-cell precursor ALL November 15, 2024Vol.50 No.43
Drugs & Targets Tempus, Flatiron collaborate to expand point of care through OncoEMR integration November 15, 2024Vol.50 No.43
Drugs & Targets Humana and Evolent expand partnership to enhance oncology care November 15, 2024Vol.50 No.43
Drugs & Targets Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product November 15, 2024Vol.50 No.43
Drugs & Targets FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients November 08, 2024Vol.50 No.42
Drugs & Targets Pangea Biomed, OHSU Knight Cancer Institute collaborate to improve cancer therapy precision November 01, 2024Vol.50 No.41
Drugs & Targets FDA approves Vyloy+chemo for gastric or GEJ junction adenocarcinoma with CLDN18.2-positive tumors October 25, 2024Vol.50 No.40
Drugs & Targets FDA accepts NDA, grants priority review for Pixclara glioma imaging agent October 25, 2024Vol.50 No.40
